Michigan's four leading research universities generate $51.4 billion in annual economic activity — 7.1% of the state's GDP — according to the presidents of Michigan State, Michigan Tech, the University of Michigan and Wayne State, who co-authored an opinion column in Bridge Michigan warning that proposed funding cuts would jeopardize both that economic engine and the pipeline of medical discoveries now moving through their labs.

The column, signed by Kevin M. Guskiewicz (Michigan State), Richard J. Koubek (Michigan Technological), Domenico Grasso (Michigan) and Richard A. Bierschbach (Wayne State), grounds its argument in a research record that R&D managers in any state legislature should recognize as portfolio-defining assets rather than cost centers.

A track record measured in outcomes

The presidents open with a specific date: July 3, 1952, when a mechanical pump built by General Motors engineers kept a 41-year-old Detroit patient, Henry Opitek, alive for 50 minutes while a surgeon repaired a damaged heart valve at Harper Hospital. Opitek lived nearly 29 more years. The pump now sits in the Smithsonian. The surgeon taught at Wayne University, since renamed Wayne State.

Three years later, a University of Michigan epidemiologist announced the results of a polio vaccine trial he had designed and evaluated himself, tracking 1.8 million children — one of the largest medical studies ever conducted. The scale matters: in 1952, polio paralyzed more than 21,000 Americans. By 1965, the number was 61.

In the 1960s, a Michigan State biophysicist and his team found that platinum compounds stop cell division, the discovery behind cisplatin, now widely used against ovarian, bladder, lung, stomach and testicular cancers. The U.S. death rate from testicular cancer has fallen by two-thirds since 1975, according to the National Cancer Institute.

In 2013, Michigan Tech turned a century of corrosion science rooted in its mining-industry origins toward bioabsorbable stents. Its researchers pioneered zinc as a stent material that dissolves at a rate matched to arterial healing — fast enough to disappear, slow enough to keep the vessel open.

What is in the pipeline today

The column separates its current research claims by maturity, and none of it has reached a patient yet — a point the presidents make explicitly.

At Michigan State, researchers have identified why ovarian cancer often stops responding to cisplatin — the drug their own institution discovered decades ago. A protein called TPPP3 acts like armor, helping cancer cells resist the drug. In the lab, blocking the protein restored cisplatin sensitivity. Patients with lower TPPP3 levels already live longer and respond better to treatment, according to the column. Teams are now working on a drug that targets TPPP3 directly and a test to flag patients at risk of resistance before it develops.

At the University of Michigan, a team says it may have found the cause of preeclampsia, the dangerous pregnancy-related blood pressure condition that has defied explanation for a century. The researchers traced three competing theories to a single gene network. Shutting the network down prevented the disease in mice and reversed its signs in human placental tissue. One member of the team had preeclampsia herself.

At Wayne State, researchers studying miscarriage report that immune-related complications differ by fetal sex from early in development — a finding suggesting that prevention strategies may ultimately need to be sex-specific.

At Michigan Tech, engineers build working replicas of individual patients' hearts, pump artificial blood through them and use lasers to track particle flow and pinpoint where clots would form. A current federal grant targets Kawasaki disease, which inflames the arteries of young children. The stated near-term application: a surgeon rehearsing an operation on a copy of a child's heart before touching the patient.

The claims and their limits

The preeclampsia and TPPP3 findings rest on mouse models, placental tissue and in-vitro work — useful preclinical signals, not clinical endpoints. The presidents themselves concede the point: none of the current work has reached a patient, and neither had the heart pump, the vaccine, the cancer drug or the dissolving stent on the day each project began. Each took years and a state willing to fund the interval between discovery and application.

The column is an advocacy document, written by institutional leaders with a direct budgetary stake in the outcome, and Bridge Michigan notes it does not endorse the views of guest contributors. But the underlying argument is quantified: $51.4 billion in annual economic activity, a figure the presidents attribute to the universities' research enterprise, and a historical conversion record that runs from a 1952 Detroit operating room to a cardiovascular modeling lab operating this morning in Houghton.

Whether state and federal funders accept that framing will determine whether the TPPP3 inhibitors, preeclampsia gene-network therapies and Kawasaki disease modeling projects now in Michigan's labs follow cisplatin's path from bench finding to standard of care — or stall at the stage the presidents say every one of these discoveries had to survive.